Press Releases

GlobeNewswire, Inc.

- 4WARD Phase 3 Chronic Neutropenia Trial Expected to Achieve Target Enrollment in Q4 2026 - - Initiating 4STEPS Phase 2b Trial Evaluating G-CSF Dose Reduction with Mavorixafor; Enrollment of First Participant Expected in Q1 2027 - - Investor Day...

GlobeNewswire, Inc.

3Q 2026 Total Revenue of $141.1 Million, Increasing 5% Year-over-Year 3Q 2026 ASCENIV Revenue of $124.7 Million, Increasing 31% Year-over-Year 3Q 2026 GAAP Net Income of $49.9 Million, Increasing 37% Year-over-Year 3Q 2026 Adjusted Net Income(1)...

GlobeNewswire, Inc.

Highlights Third quarter 2026 revenue was $202.7 million, representing a 6% sequential increase and a 1% decrease year-over-year.

GlobeNewswire, Inc.

BURLINGTON, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q3 2026 results, announced a quarterly dividend of $0.25/share, and provided...

GlobeNewswire, Inc.

Third quarter 2026 net sales of $9.7 million, an increase of 12% over $8.7 million in the third quarter of 2025 Net loss of $1.3 million decreased 61% from prior year with Adjusted EBITDA net loss improving 67% from prior-year period Company to...

GlobeNewswire, Inc.

Ribupatide oral global Phase 3 program expected to begin in 1H 2027 following completion of End-of-Phase 2 meeting with FDA Ribupatide injection Phase 2b trial and KaiNETIC global Phase 3 program fully enrolled; data expected mid-2027 and...

GlobeNewswire, Inc.

VAX-31 Adult Indication: Announced Positive Topline Data from OPUS-1 Pivotal Phase 3 Trial; VAX-31 Met All Prespecified Primary Endpoints, Was Well Tolerated and Demonstrated a Safety Profile Similar to PCV20 and PCV21 Across All Ages Studied...

GlobeNewswire, Inc.

Revenue of $195.1 million, up 3% year-over-year, above the midpoint of the Company’s guidance range Subscription revenue of $139.7 million, up 11% year-over-year, marking the sixth consecutive quarter of double digit-subscription revenue growth...

GlobeNewswire, Inc.

- Duchenne (SGT-003): SGT-003 has been generally well tolerated in the 53 participants dosed in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of November 3, 2026 - - Solid has scheduled a Type C meeting with the FDA in late Q4 2026 to discuss...

GlobeNewswire, Inc.

Received U.S. FDA approval and launched RASONQUE® (daraxonrasib) for adult patients with metastatic pancreatic cancer who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy Reported RASONQUE...

GlobeNewswire, Inc.

Advancing Strategic Initiatives Across Credit and Real Estate to Drive Growth and Expand Fee-Paying AUM Strong Balance Sheet with Over $43 Million of Cash and Cash Equivalents to Support Continued Growth Initiatives Monomoy REIT Continued...

GlobeNewswire, Inc.

-- Announces PANORAMA, an OnKure-sponsored, large-scale, multiregional registry designed to characterize the natural disease course and treatment patterns of people living with vascular anomalies -- Executing IND-enabling activities for...

GlobeNewswire, Inc.

MENLO PARK, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to...

GlobeNewswire, Inc.

-- CLARITY-101 Phase 1/1b clinical trial initiated and cleared by multiple global regulatory authorities, including the U.S. Food and Drug Administration (FDA) -- -- New preclinical data highlighting DMR-001’s potentially best-in-class pan-mutant...

GlobeNewswire, Inc.

- Revenues up 5% to $334.1 Million and Gross Billings up 3% to $2.40 Billion - VANCOUVER, Wash., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Barrett Business Services, Inc. (“BBSI” or the “Company”) (NASDAQ: BBSI), a leading provider of business management...

GlobeNewswire, Inc.

Annualized recurring revenue (“ARR”) of $820 million Total revenue of $212 million; Product subscriptions revenue of $206 million GAAP income from operations of $9.0 million; Non-GAAP income from operations of $46.2 million Net cash provided by...

GlobeNewswire, Inc.

– Commercialization plans for lorundrostat are on track ahead of PDUFA target date of December 22, 2026 – – New analyses from the pivotal Launch-HTN trial showed 46% of participants with uncontrolled or resistant hypertension receiving...

GlobeNewswire, Inc.

Phase 3 ReDiscover-2 trial in 2L breast cancer expected to complete enrollment in mid-2027 Updated data from ongoing Phase 1/2 ReInspire trial of zovegalisib in vascular anomalies to be featured in oral presentation at the 68th American Society of...

GlobeNewswire, Inc.

Received Regenerative Medicine Advanced Therapy (RMAT) Designation from U.S. FDA for TN-401 Gene Therapy for PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy TN-201 and TN-401 Program Updates on Upcoming Data Readouts and Regulatory...

GlobeNewswire, Inc.

Third Quarter 2026 Highlights: Revenue of $209.4 million, compared with $165.9 million in the same period last year GAAP net income of $13.6 million, or $0.21 per diluted share, compared with $10.6 million, or $0.17 earnings per diluted share in...